Persistence of high-level (1,3)-β-D-glucan after candidemia following autologous peripheral SCT in a pediatric patient.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Beta-D-Glucan in Patients with Haematological Malignancies.Journal of fungi (Basel, Switzerland) · 2021
   Review
2. Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.Frontiers in microbiology · 2018
   Review
3. Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children.Journal of the Pediatric Infectious Diseases Society · 2017
   Review
4. Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children.Journal of fungi (Basel, Switzerland) · 2016
   Review
5. β-D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Journal of clinical microbiology · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as